Free Trial
NASDAQ:GNFT

Genfit (GNFT) Stock Price, News & Analysis

Genfit logo
$4.09 +0.04 (+0.99%)
(As of 10:43 AM ET)

About Genfit Stock (NASDAQ:GNFT)

Key Stats

Today's Range
$4.09
$4.24
50-Day Range
$4.05
$6.37
52-Week Range
$3.12
$6.42
Volume
839 shs
Average Volume
16,079 shs
Market Capitalization
$204.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00
Consensus Rating
Buy

Company Overview

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Genfit Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
37th Percentile Overall Score

GNFT MarketRank™: 

Genfit scored higher than 37% of companies evaluated by MarketBeat, and ranked 802nd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Genfit has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Genfit has only been the subject of 1 research reports in the past 90 days.

  • Read more about Genfit's stock forecast and price target.
  • Earnings Growth

    Earnings for Genfit are expected to decrease in the coming year, from $0.98 to ($0.58) per share.

  • Price to Book Value per Share Ratio

    Genfit has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.13% of the float of Genfit has been sold short.
  • Short Interest Ratio / Days to Cover

    Genfit has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Genfit has recently decreased by 0.79%, indicating that investor sentiment is improving.
  • Dividend Yield

    Genfit does not currently pay a dividend.

  • Dividend Growth

    Genfit does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.13% of the float of Genfit has been sold short.
  • Short Interest Ratio / Days to Cover

    Genfit has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Genfit has recently decreased by 0.79%, indicating that investor sentiment is improving.
  • News Sentiment

    Genfit has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Genfit this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Genfit insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.20% of the stock of Genfit is held by insiders.

  • Percentage Held by Institutions

    Only 2.24% of the stock of Genfit is held by institutions.

  • Read more about Genfit's insider trading history.
Receive GNFT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

GNFT Stock News Headlines

This company will win the AI race
Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.
Genfit’s Revenue Surge Driven by Key Milestone
GENFIT Reports Third Quarter 2024 Financial Information
See More Headlines

GNFT Stock Analysis - Frequently Asked Questions

Genfit's stock was trading at $3.85 at the beginning of the year. Since then, GNFT shares have increased by 6.2% and is now trading at $4.09.
View the best growth stocks for 2024 here
.

Genfit (GNFT) raised $132 million in an initial public offering on Wednesday, March 27th 2019. The company issued 5,000,000 shares at a price of $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Genfit investors own include Intercept Pharmaceuticals (ICPT), InterDigital (IDCC), NVIDIA (NVDA), Occidental Petroleum (OXY), Vaxart (VXRT), American Airlines Group (AAL) and Carnival Co. & (CCL).

Company Calendar

Today
12/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GNFT
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.00
High Stock Price Target
$13.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+221.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$41.31 million
Book Value
$1.48 per share

Miscellaneous

Free Float
47,893,000
Market Cap
$202.46 million
Optionable
Not Optionable
Beta
1.25
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:GNFT) was last updated on 12/3/2024 by MarketBeat.com Staff
From Our Partners